SCHEMBL12780980

SCHEMBL12780980

Nc1nc(Nc2ccc(Cl)cc2)nn1-c1nc2ccccc2s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 4/20 0.62
RAB9A P51151 7/20 0.53
NPC1 O15118 6/20 0.53
MAPT P10636 6/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
AXL P30530 2/20 0.51
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAPK1 P28482 2/20 0.45
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 1/20 0.44
HPGD P15428 1/20 0.44
ALOX12 P18054 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
LMNA P02545 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
HTT P42858 2/20 0.44
HSP90AA1 P07900 1/20 0.44
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12780866 0.90 BACE1 (0.64) BACE1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12779066 0.90 BACE1 (0.63) BACE1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12780934 0.88 BACE1 (0.62) BACE1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12780898 0.88 BACE1 (0.62) BACE1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12780946 0.88 BACE1 (0.62) BACE1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12780961 0.87 BACE1 (0.66) BACE1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12780947 0.87 BACE1 (0.58) BACE1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12780987 0.85 BACE1 (0.59) BACE1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12780837 0.85 BACE1 (0.67) BACE1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12780873 0.85 BACE1 (0.61) BACE1RAB9ANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885RAB9A 3309/4885NPC1 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.